Hematology Month in Review: June 2025

Despite issuing no major approvals of hematology medications, the US Food and Drug Administration (FDA) granted several Orphan Drug and Fast Track designations to various drugs throughout June, from a hereditary hemorrhagic telangiectasia treatment to an oral drug for chronic neutropenia. Additionally, multiple drugs were successful in their respective studies, with iptacopan achieving its primary endpoint in a phase 3 trial and denecimig proving its tolerability in hemophilia A after switching from emicizumab.